INTRODUCTION
The interconversion of epithelial and mesenchymal properties underlies key elements of embryonic development, including the generation of cellular lineages essential to formation of the kidney, heart valves and neural crest-derived tissues (1, 2) . EMT converts stationary epithelial cells into migratory mesenchymal cells, with loss of apicobasal cell polarity and gain of stem-like features and apoptosis resistance (3, 4) . Its aberrant activation in cancer has been linked to increased invasiveness into the bloodstream, culminating in the generation of circulating tumor cells (CTCs), which may initiate distant metastases (1) . While its role is less well defined in tumorigenesis, the opposite transformation, Mesenchymal-toEpithelial Transition (MET), has been postulated to play a role in the subsequent reversion of CTCs to a less migratory and more proliferative state at distant metastatic sites (5) . Accumulating evidence for the relevance of EMT in human cancer include the finding of increased mesenchymal signatures in CTCs from patients with metastatic breast cancer (6) .
Signaling pathways known to initiate or modulate EMT include TGF-ß, Wnt, Notch, EGF, HGF, FGF and HIF (2, 7, 8) . These cellular signals lead to the activation of master transcriptional regulators, such as Snai1, Snai2, Twist, genes and the induction of mesenchymal markers (9) . The complexities of the initial signaling pathways and the subsequent transcriptional outputs have limited efforts to target EMT therapeutically. However, the identification of key, "druggable" downstream effectors would enable the testing and validation of EMT as a therapeutic target in suppressing cancer metastasis.
The use of shRNA screens to reveal potential therapeutic targets modulating complex cellular processes is well established (10) (11) (12) (13) . We recently used a pooled whole genome shRNA library screen to identify 31 distinct genes whose knockdown increases cellular migration in MCF10A breast epithelial cells (14) .
Functional analysis of these hits revealed that they function through a common effector, the Ser/Thr kinase (RSK), whose inhibition abrogates mammalian cell migration (14) . To extend this analysis to an even more complex phenotype such as EMT, we established an RNA expression signature of epithelial versus mesenchymal cell fates, which could be quantified in high throughput using a microarrayed format. Using a kinome shRNA library, we identified mitogenactivated protein kinase 7 (MAPK7, also known as ERK5 and BMK1), an effector of RSK, as a modulator of epithelial cell properties. Knockdown of MAPK7 enhances epithelial cell characteristics (i.e., MET) and suppresses the bloodborne metastatic potential of human breast cancer cells in a mouse model.
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MATERIALS AND METHODS
Tissue culture and Plasmids
MCF10A cells were cultured as described (15) . MCF10A:Myc cells were generated by transduction with a lentiviral c-Myc encoding construct. A549, PANC1 and MDA-MB-231 (4175 TGL variant) cells were grown according to the American Type Culture Collection (ATCC) recommendations. All cell lines were obtained, immediately expanded and frozen at early passages. When thawed for experimental use, they were never passaged more than 4 months in culture. All cell lines were tested for mycoplasma contamination giving negative results.
Lentiviral vectors containing WT-MAPK7, DN-MAPK7 or Myr-MAPK7 were kindly provided by Dr. Zhengui Xia (University of Washington, Seattle). For Boyden chamber cell migration assays, cultures were set up when confluency of 50%-75% was reached as described (14) .
Primary shRNA screen
The Broad Institute RNAi Consortium (TRC) kinome collection of lentiviral shRNAs (16) was arrayed for testing. Briefly, MCF10A:Myc cells were infected at a multiplicity of infection (MOI) of 0.3 in 96 well plate and selected using 2 ug/mL puromycin for two days, after which cells were trypsinized and split 1:3 into a new 96 well plate. The panomics multiplex quantigene assays were performed after three days, according to the manufacturer's protocols. 
Immunoblot analysis
Cells were harvested in RIPA buffer (Roche). Cell lysates were cleared by centrifugation at 14,000 rpm for 10 min at 4°C. For immunoblotting analysis, lysates were loaded onto 4-15% SDS-PAGE gels (Bio-Rad), and subsequently transferred onto Immobilon PVDF membrane (Millipore). Proteins were visualized with Western Lightning Plus chemiluminescence kit (Perkin Elmer). Antibodies 
qRT-PCR and knockdown studies
RNA was extracted using RNeasy Minikit (Qiagen) and cDNA synthesis was performed using SuperScript III reverse transcriptase (Invitrogen). qRT-PCR quantitation with Power SYBR Green PCR Master Mix (Applied Biosystems) was applied. The sequences of the PCR primer pairs are listed in Table S1 . All samples were done in triplicate and the relative abundance of transcripts was derived by standardizing the input to the control signal, GAPDH. To test for knockdown of target transcripts, cells were plated in 6-well plates and spininfected the next day with individual lentiviruses at an approximate MOI of 1-3.
Puromycin selection (at 2 ug/mL) was added at 2 days, and after another 2 days, cells were re-plated to 6 cm 2 dishes; RNA and lysates were collected for the knockdown confirmation. 
RNAi Assays
A pool of four siRNAs (smartpool) targeting GAPDH and Snai2 was used along with a nontargeting (control smartpool) siRNA from Dharmacon. RNAi transfection was performed according to manufacturer's protocol. Knockdown of GAPDH and Snai2 were performed 48 hrs prior to RNA extraction. cDNA was synthesized and qRT-PCR was performed as described above. All samples were done in triplicate, and the relative abundance of transcripts was derived by standardizing the input to the control signal, β-actin.
Immunofluorescence microscopy
Cells were fixed in EM grade 4% formaldehyde and permeabilized with 0.1% Triton X-100 and staining with primary antibodies CDH1 (BD Biosciences) and Vimentin (VIM, Santa Cruz) was carried out overnight at 4ºC. Alexa594-conjugated goat-anti-mouse secondary antibody (Molecular Probes) was used for primary mouse monoclonal antibodies and Alexa-488 conjugated goat-antirabbit secondary antibody was used for primary rabbit polyclonal antibodies (Molecular Probes). Nuclei were visualized using DAPI. Resource Facility, and chips were functionalized using biotinylated antibodies as previously described (17) 
Tumor Generation and Analyses
RNA-in situ hybridization
For quantiGene ViewRNA in-situ hybridization (ISH) on FFPE-tissue, a dual- 
ISH Scoring
For ISH scoring, both mesenchymal and epithelial components of the tumor were scored separately for intensity of the staining: staining observed on 2X magnification is scored as 3, on 20X magnification is scored as 2, on 40X magnification is scored as 1 and no staining even on 40X magnification is scored as 0 (Table S2) 
Statistical and Bioinformatic Analyses
The computation of the FDR estimates used to construct Figure 1B 
RESULTS
Arrayed kinome shRNA screening using an EMT gene expression signature
We defined and optimized an EMT expression signature for microarrayed screening using a highly sensitive and quantitative RNA-based assay (Panomic quantigene, Affymetrix, Santa Clara, CA). Candidate EMT markers were selected from microarray-based expression profiling of immortalized, non-transformed MCF10A human mammary epithelial cells, following ectopic expression of the known EMT inducers Snai1 and Twist (18, 19) . We selected a total of 26 markers, including epithelial markers (N=9), mesenchymal markers (N=10) and known regulators of EMT (N=7) ( Table 1) .
MCF10A cells can undergo further specification in either epithelial or mesenchymal direction, making them ideal for manipulations that either enhance or suppress their epithelial properties (20) (21) (22) (23) spontaneously assume mesenchymal features when grown at low cell density, a characteristic that prohibits a large-scale microarrayed screen (24, 25) . Ectopic expression of c-Myc in MCF10A cells is known to suppress this cell densitydependent effect, and we therefore adapted Myc-expressing variants (MCF10A:Myc cells) for the screen (Figure S1A) (26, 27) . These cells remain sensitive to EMT-inducing stimuli, including overexpression of Snai1, YAP, SIP1 or Zeb1 genes, as well as treatment with TGF-ß ( Figure 1A) .
The outline of the kinome shRNA screen, performed using an arrayed 96-well plate format (constructs from the RNAi Consortium, Broad Institute), is illustrated in Figure S1B . Since full EMT phenotypes may only become evident after a few days, cells were trypsinized after infection and reseeded to allow continued proliferation. Each plate included negative and positive controls; cells infected with the EMT-inducer YAP are shown, demonstrating robust EMT as measured using the 26 gene-set signature ( Figure 1A) . The Panomics quantigene assay allowed simultaneous detection and quantitation of the effect of individual RNA hairpins on all the markers in our EMT signature.
We observed that the effect of cell density on EMT was greatly reduced but not abolished by constitutive expression of c-Myc. We therefore established analytic parameters to exclude the effect of cell density on EMT measurements by 
combined marker analysis, while a small set of other kinases were identified by the different analytic methods. Given its known association with an adverse prognosis in cancers of the brain, breast, colon and lymphomas (29-32), we selected MAPK7 for more detailed functional analyses.
Knockdown of MAPK7 induces expression of epithelial markers
To begin to define its effects on tumorigenic properties, we first validated MAPK7 (Figure 2A, Figure S5A ). In A549 lung cancer cells (Figure 2A-B ( Figure S6B-C) .
DISCUSSION
The suppression of metastasis remains one of the most important and poorly addressed challenges in cancer therapy. Here, we sought to tackle the interconversion between epithelial and mesenchymal cell fates, which is thought to constitute a critical component of epithelial cancer invasion and metastasis.
We used an arrayed kinome shRNA library to interrogate non-transformed MCF10A cells for expression of an EMT RNA signature, and confirmed hits using tumorigenic cancer cell lines. We did not uncover an individual kinase whose knockdown was sufficient to trigger EMT in MCF10A cells, suggesting that the maintenance of epithelial phenotypes may be dependent upon multiple pathways. In contrast, the individual knockdown of several kinases resulted in an increased epithelial phenotype. Thus, baseline mesenchymal properties of MCF10A cells appear to be maintained by the activity of these kinases, whose suppression leads to enhanced epithelial gene expression. MAPK7 is known to be activated by stress and growth factor signaling, in part through its upstream mitogen-activated kinase kinase 5 (MEK5) (36) . In turn, MAPK7 has been implicated in diverse phenotypes, ranging from resistance to TNF-α (37) and regulation of estrogen receptor expression (38) to migration of epithelial cells in response to Hepatocyte Growth Factor (HGF) and of keratinocytes during wound healing (31, 39, 40 
consistent with previous reports, which have also linked these effects to its regulation of expression of EMT master regulators (37, 38, 40) . Whereas in A549 cells, suppression of MAPK7 induces expression of Snai2, but not other transcriptional regulators of EMT, MAPK7 may also regulate Zeb1 in some other cell types (37) .
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